Clinical Trial Update: An Observational Study Evaluating Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in Multiple Sclerosis (MS) Patients

View source ↗

Summary

This completed observational study evaluated whether high-frequency and higher-dose administration of Rebif (interferon beta-1a) could optimize therapy in relap…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Rebif (interferon beta-1a)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Relapsing-Remitting Multiple Sclerosis | Status: COMPLETED